| Bioactivity | ML-SA1, as a selective TRPML agonist, inhibits Dengue virus 2 (DENV2) and Zika virus (ZIKV) by promoting lysosomal acidification and protease activity. The IC50 value of ML-SA1 against DENV2 RNA and ZIKV RNA is 8.3 μM and 52.99 μM, respectively. ML-SA1 induces autophagy. ML-SA1 can be used for the research of broad-spectrum antiviral[1]. | ||||||||||||
| Target | IC50: 8.3 μM (DENV2).IC50: 52.99 μM (ZIKV) | ||||||||||||
| Invitro | ML-SA1 (25 μM; 0~14 hours; A549 cells) possibly affects the entry of DENV2 into host cells[1].ML-SA1 (0~200 μM; A549 cells) shows that there is no cytotoxicity to the cell line observed, even at concentrations up to 200 μM. ML-SA1 (0~50 μM; A549 cells) significantly suppresses DENV2 at the RNA levels and the IC50 is 8.93 μM[1].ML-SA1 results in a dose-dependent decrease in ZIKV in A549 cells at both the RNA and protein levels, and the IC50 value of ML-SA1 against ZIKV RNA is 52.99 μM. ML-SA1, as an activator of TRPMLs, appears to be a potent inhibitor of DENV2 and ZIKV in vitro. ML-SA1 promotes lysosomal acidification and protease activity to inhibit viral infection. ML-SA1 can induce autophagy in Huh7 cells or A549 cells[1]. Western Blot Analysis[1] Cell Line: | ||||||||||||
| Name | ML-SA1 | ||||||||||||
| CAS | 332382-54-4 | ||||||||||||
| Formula | C22H22N2O3 | ||||||||||||
| Molar Mass | 362.42 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Xia Z, et al. ML-SA1, a selective TRPML agonist, inhibits DENV2 and ZIKV by promoting lysosomal acidification and protease activity. Antiviral Res. 2020;182:104922. |